Augusto J Mendes, Federica Ribaldi, Aurelien Lathuiliere, Nicholas J Ashton, Henrik Zetterberg, Marc Abramowicz, Max Scheffler, Frédéric Assal, Valentina Garibotto, Kaj Blennow, Giovanni B Frisoni
BACKGROUND: Plasma biomarkers of Alzheimer's disease (AD) pathology, neurodegeneration, and neuroinflammation are ideally suited for secondary prevention programs in self-sufficient persons at-risk of dementia. Plasma biomarkers have been shown to be highly correlated with traditional imaging biomarkers. However, their comparative predictive value versus traditional AD biomarkers is still unclear in cognitively unimpaired (CU) subjects and with mild cognitive impairment (MCI). METHODS: Plasma (Aβ42/40, p-tau181, p-tau231, NfL, and GFAP) and neuroimaging (hippocampal volume, centiloid of amyloid-PET, and tau-SUVR of tau-PET) biomarkers were assessed at baseline in 218 non-demented subjects (CU = 140; MCI = 78) from the Geneva Memory Center...
May 16, 2024: Alzheimer's Research & Therapy